NewEdge Wealth LLC Grows Stock Holdings in Stryker Corporation $SYK

NewEdge Wealth LLC boosted its holdings in Stryker Corporation (NYSE:SYK) by 44.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,257 shares of the medical technology company’s stock after buying an additional 3,472 shares during the period. NewEdge Wealth LLC’s holdings in Stryker were worth $3,957,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in SYK. United Financial Planning Group LLC purchased a new position in shares of Stryker during the 3rd quarter valued at $27,000. CGC Financial Services LLC purchased a new position in shares of Stryker during the 4th quarter valued at $29,000. Strive Asset Management LLC purchased a new position in shares of Stryker during the 3rd quarter valued at $30,000. ANTIPODES PARTNERS Ltd purchased a new position in shares of Stryker during the 3rd quarter valued at $34,000. Finally, Copia Wealth Management grew its position in shares of Stryker by 181.6% during the 3rd quarter. Copia Wealth Management now owns 107 shares of the medical technology company’s stock valued at $40,000 after purchasing an additional 69 shares in the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Stock Performance

NYSE SYK opened at $282.85 on Tuesday. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $404.87. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The company has a market capitalization of $108.33 billion, a P/E ratio of 32.74, a P/E/G ratio of 1.80 and a beta of 0.80. The company has a fifty day moving average of $336.33 and a 200-day moving average of $353.81.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. During the same period in the prior year, the firm posted $2.84 earnings per share. The business’s revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities research analysts predict that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s payout ratio is currently 40.74%.

Analyst Ratings Changes

A number of research firms have recently commented on SYK. JPMorgan Chase & Co. reduced their price target on shares of Stryker from $445.00 to $400.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Robert W. Baird set a $385.00 price target on shares of Stryker in a research report on Friday, May 1st. Piper Sandler restated an “overweight” rating on shares of Stryker in a research report on Tuesday, January 27th. Truist Financial restated a “hold” rating and set a $330.00 price target (down from $380.00) on shares of Stryker in a research report on Monday, May 4th. Finally, Needham & Company LLC reduced their price target on shares of Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Sixteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $395.48.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.